A89.F Adocia SA
- Market cap
- EUR 95.4M
- P/E
- -
- P/B
- 28.18x
- ROE
- -1,112.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is A89.F undervalued?
Graham numberThe Graham number of Adocia SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Adocia SA fundamental analysis
No fundamental analysis for Adocia SA yet.
Adocia SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Adocia SA
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. The company's proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone GLP-1 Amylin, a combination of acting insulin glargine and rapid-acting insulin lispro, as well a…
Full company profileAdocia SA financial statements
Adocia SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 22.5M | 19.5M | 47.4M | 2.14M | 841K | 1.44M | 11.4M | 2.15M | 9.32M | 1.48M |
| Gross Profit | 20.7M | 17.7M | 45.2M | 437K | -616K | 180K | 9.61M | 1.39M | 8.20M | 683K |
| Operating Income | -45.7M | -42.5M | 9.71M | -22.0M | -21.1M | -19.4M | -1.70M | -14.2M | -7.40M | -15.8M |
| EBITDA | - | -7.39M | 13.0M | -20.0M | -20.0M | -19.3M | -3.58M | -19.4M | -6.91M | -15.4M |
| Net Income | -7.89M | -8.55M | 7.62M | -18.6M | -23.3M | -22.8M | -6.90M | -21.2M | -9.32M | -16.6M |
| EPS | - | -1.24 | 1.10 | -2.68 | -3.34 | -3.15 | -0.79 | -1.50 | -0.60 | -0.85 |
| Balance Sheet | ||||||||||
| Total Assets | 78.8M | 53.8M | 70.0M | 62.0M | 45.2M | 30.1M | 30.6M | 25.0M | 27.0M | 28.5M |
| Total Liabilities | 36.0M | 16.9M | 24.2M | 33.9M | 38.8M | 43.9M | 43.6M | 31.9M | 30.1M | 27.0M |
| Shareholders' Equity | 42.8M | 36.9M | 45.8M | 28.0M | 6.33M | -13.8M | -13.0M | -6.91M | -3.09M | 1.49M |
| Cash & Short-term Investments | 58.0M | 34.8M | 39.8M | 43.7M | 28.1M | 15.2M | 17.4M | 13.0M | 7.53M | 17.3M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -13.1M | -22.2M | 6.31M | -9.66M | -21.9M | -19.2M | -15.0M | -4.95M | -15.6M | -6.53M |
| Capital Expenditure | 8.08M | 1.98M | 784K | 2.02M | 205K | 361K | 153K | 156K | 229K | 267K |
| Free Cash Flow | - | -24.2M | 5.53M | -11.7M | -22.1M | -19.6M | -15.1M | -5.11M | -15.8M | -6.80M |
| Ratios | ||||||||||
| ROE | -18.5% | -23.2% | 16.6% | -66.3% | -368.2% | - | - | - | - | -1,112.7% |
| ROA | -10.0% | -15.9% | 10.9% | -30.0% | -51.6% | -75.7% | -22.5% | -84.8% | -34.5% | -58.3% |
| Net Profit Margin | -35.1% | -43.9% | 16.1% | -868.1% | -2,773.4% | -1,575.8% | -60.3% | -984.3% | -100.0% | -1,124.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Adocia SA dividends
Adocia SA has not paid dividends in the last 10 fiscal years.
Who owns Adocia SA
- Insiders 8.81%
- Institutions 7.00%
- Public & others 84.19%
- Shares outstanding 21.9M
- Free float 17.0M
Adocia SA company profile
- Company name
- Adocia SA
- Ticker
- A89.F
- ISIN
- FR0011184241
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 80
- Fiscal year end
- December
- Address
- 115 Avenue Lacassagne, Lyon, France, 69003
- Phone
- 33 4 72 61 06 10
- Website
- adocia.com
About Adocia SA
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. The company's proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone GLP-1 Amylin, a combination of acting insulin glargine and rapid-acting insulin lispro, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity, including AdoShell Islets, an ultra rapid insulin; AdOral Sema, an oral form of GLP-1 semaglutide; and AdoXLongSem, a long-lasting injectable formulation of semaglutide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
Adocia SA management
8- Mr. Olivier Soula M.B.A., Ph.D.Co-Founder, CEO & Director · born 1970
- Mr. Mathieu-William GilbertCOO & CFO
- Jeremy Benattar Eng., Pharm.D.Marketing & Strategy Director
- Ms. Geraldine Favre SoulaDirector of Human Resources
- Dr. Bertrand AlluisHead of the Analysis Department and Project Manager
- Dr. David DuracherHead of the Pharmaceutical Development & Physical Chemistry Departments and Project Manager
- Dr. Richard CharvetHead of Chemistry Department & Project Manager
- Dr. Grégory MeiffrenHead of the Biology Department & Project Manager